A study reports that dual epigenetic markers in cell-free DNA achieved 95% diagnostic accuracy for stage I colorectal cancer, outperforming conventional liquid biopsy methods.
A University of Warwick study finds AI cancer detection models may rely on statistical correlations rather than true biomarker signals, raising concerns about reliability in clinical pathology applications.
Swiss company's 1536-well technology aims to make transcriptomics cost-effective for primary drug screening and toxicology applications.
The AI companion analyzes up to five years of personal lab data within the company's patient portal to explain test results and identify health trends.
Thermo Fisher Scientific has opened an $18 million, 8,000-square-meter distribution and labeling center in Uppsala, Sweden, to support global supply of immunodiagnostics for allergy and autoimmune disease testing.
